Abstract: A market survey of 317 hospitals, conducted by the Enterprise Analysis Corporation in 2007 and updated in 2008, reveals substantial growth in the number of hospitals performing point-of-care testing (POCT). The prevalence of POCT has increased across all disciplines (except blood glucose, which POC technology has fully penetrated). Of particular note, 87% of the surveyed hospitals were found to perform POC coagulation testing and 77% were found to perform blood gas/electrolyte testing. Sales trend data examining purchase intent suggests continued growth in POCT.
"Although widespread use of pharmacogenomic tests has not yet arrived, manufacturers want to make sure that they’re not left out when the time comes, said EAC’s Farber. 'People are really starting to come to grips with the reality of companion diagnostics, and we’re now getting very serious inquiries about where the market is going and how a company can position itself to do something about it.'"
Abstract: The objective of this article was to assess if the 2007-2009 recession impacts point-of-care (POC) testing; if the effect for POC in hospitals is worse, about the same, or not as stressful as the central laboratory; and whether POC testing in hospitals and in the consumer sector continues to grow. An additional goal is to make some rough projections for the next few years and consider a high-level view of the POC sector of the in vitro diagnostics (IVD) industry. For the purposes of this article, we take a broad view of POC testing and use Dr Kricka's definition (Point of Care 2009;8:42-44), which includes home, pharmacy, supermarket, physician office, and the hospital bedside.
We use the Enterprise Analysis Corporation's (EAC's) "Global IVD Scenario Model" (the EAC's Global IVD Industry Scenario Model contains a database of past, current, and projected sales for 85 companies in 16 disciplines for 9 years: historical sales for the past 3 years, data for the current year, and EAC-prepared projections for the next 5 years. The model is updated quarterly; it has been in use at EAC since 2006) to estimate total IVD sales and POC's share, as well as to prepare projections for future sales, and analyze the covered population of the top 85 companies. To obtain data on the current impact of the recession, a possible differential impact on POC testing and its expected near-term impact, we conducted a brief market research survey in a population of 130 US hospital respondents.
The study indicates that the short answer is yes and concludes that the recession has a notable impact in all sectors of POC and that the impact is especially strong in whole-blood glucose testing. On a more positive note, the study finds that general POC testing, that is, POC without whole-blood glucose, can look forward to continued growth in the long term, 2015 time frame, in fact at an increased growth rate in the range of 8% to 9%. Finally, the assessment indicates that the projected mid- to long-term growth of the POC market segment is attracting a number of companies to develop some innovative technologies to better satisfy perceived customer needs.
Abstract: The market for self-monitoring of blood glucose (SMBG) approached $8.8 billion worldwide in 2008. Yet despite dramatic double-digit growth in sales of SMBG products since 1980, the business is now facing declining prices and slower dollar growth. Given that SMBG meters and test strips are viewed by consumers and insurers as essentially generic products, it will be extremely challenging for new market entrants to displace well-entrenched existing competitors without a truly innovative technology. Also, in the face of declining glucose test strip prices, market expansion can only occur through identification of more of the undiagnosed diabetes population and convincing existing diabetes patients to adopt glucose testing or to test more frequently. Ultimately, a combination of technology innovations, patient education, and economic incentives may be needed to significantly expand the SMBG market and build sustainable long-term dollar growth for SMBG vendors.
"Laboratorians have been talking about personalized medicine and companion diagnostics at least since the availability of her2/neu testing more than a decade ago. Hughes recalled a forecast then that by now, personalized medicine would be a huge market. This segment remains relatively small in the grand scheme of things, yet its great potential remains, he said. "What’s attractive about these tests is that they have the potential to be priced at a very high value, such as the Oncotype DX breast cancer model where you can potentially save tens of thousands of dollars in unnecessary chemotherapy, so your test can command a much higher price." While such tests will never reach the high volumes of routine chemistry panels or CBC, they won’t be priced at a nickel a test either, said Hughes."